American Journal of Medical Sciences and Medicine, 2023, Vol. 11, No. 4, 98-101
Available online at http://pubs.sciepub.com/ajmsm/11/4/1
Published by Science and Education Publishing
DOI:10.12691/ajmsm-11-4-1

Efficacy of OCTA-H and Octa-Gel Against Herpes Simplex Virus Type 1 Infection

Hesham Mohamed Abdal-Salam Yehia[1,*], Said Mahmoud Said[2]

[1]Department of Biotechnology, HST Company, Cairo, Egypt
[2]Department of Biotechnology, HST Company
*Corresponding author: heshamyehia@gmail.com

Received October 05, 2023; Revised November 08, 2023; Accepted November 15, 2023

Abstract Herpes simplex virus type 1 (HSV-1) is a member of the Herpesviridae family and is a common human pathogen. Herpes simplex virus type 1 (HSV-1) infection is a highly prevalent viral infection that affects a large portion of the population worldwide. The development of effective antiviral agents to combat HSV-1 is of great importance. In this study, we aimed to evaluate the efficacy of two potential antiviral candidates, OCTA-H and Octa-Gel, against HSV-1 infection. The assay was conducted using a BSC-III cabinet level 3 III under Germfree conditions to ensure accurate assessment of antiviral activity. The results demonstrated that both OCTA-H and Octa-Gel exhibited significant antiviral activity against HSV-1, with OCTA-H demonstrating a higher level of efficacy compared to Octa-Gel. These findings highlight the potential of OCTA-H as a promising candidate for further development as an antiviral agent against HSV-1.

Keywords: *OCTA-H, Octa-Gel, HSV-1, antiviral activity, efficacy*

Cite This Article: Hesham Mohamed Abdal-Salam Yehia, and Said Mahmoud Said, "Efficacy of OCTA-H and Octa-Gel Against Herpes Simplex Virus Type 1 Infection." *American Journal of Medical Sciences and Medicine*, vol. 11, no. 4 (2023): 98-101. doi: 10.12691/ajmsm-11-4-1.

1. Introduction

HSV-1 is primarily associated with infections of the mouth, pharynx, face, eye, and central nervous system (CNS). It is commonly transmitted through oral contact, such as kissing or sharing utensils. HSV-1 infections often manifest as cold sores or fever blisters on or around the lips [1]. However, HSV-1 can also cause more severe infections, such as herpes encephalitis (inflammation of the brain) or ocular herpes (eye infection). HSV-2 is primarily associated with infections of the anogenital region, including the genitals, buttocks, and anal area [2]. It is mainly transmitted through sexual contact. Genital herpes caused by HSV-2 is a sexually transmitted infection (STI). However, it is important to note that both HSV-1 and HSV-2 can cause infections in any area of the body, depending on the mode of transmission and specific circumstances [3].

It is worth mentioning that HSV-1 and HSV-2 can be transmitted even when there are no visible symptoms or active lesions [4]. This is known as asymptomatic shedding, and it contributes to the high prevalence and transmission rate of the virus. Proper education, practicing safe sex, and maintaining good personal hygiene can help reduce the risk of HSV transmission. Additionally, antiviral medications are available to manage outbreaks and reduce the frequency and severity of recurrences [5].

It is responsible for a wide range of infections, including oral and facial infections, ocular infections, and infections of the central nervous system [6]. To better understand the virus and its mechanisms of infection, it is important to explore the components that make up HSV-1 as depicted in Figure 1.



Figure 1. The components that make up HSV-1 [7]

- Viral Envelope:
  The outermost layer of HSV-1 is the viral envelope. It is derived from the host cell membrane during the process of viral budding. The envelope is studded with viral glycoproteins, including glycoprotein B (gB), glycoprotein C (gC), glycoprotein D (gD), and glycoprotein H (gH). These glycoproteins play crucial roles in viral

attachment, entry, and fusion with the host cell membrane [8].

- Capsid:
  Beneath the viral envelope lies the capsid, a protein shell that encloses the viral genome. The HSV-1 capsid is icosahedral in shape and is composed of multiple copies of three major viral proteins: VP5, VP19C, and VP23. The capsid protects the viral genome from degradation and aids in its transport during viral replication [9].
- Viral Genome:
  The HSV-1 genome consists of a linear, double-stranded DNA molecule. It is relatively large, with a size of approximately 152 kilobase pairs (kbp). The viral genome encodes for more than 80 proteins that are involved in various stages of the viral life cycle. These proteins are responsible for viral replication, gene expression, and evasion of the host immune response [10].
- Tegument:
  The space between the viral envelope and the capsid is filled with a layer of proteinaceous material known as the tegument. The tegument contains a complex mixture of viral and host proteins that play important roles in viral replication, gene expression, and modulation of the host immune response. Some tegument proteins, such as VP16, VP22, and VP13/14, are involved in the regulation of viral gene expression [11].
- Viral Proteins:
  HSV-1 encodes a variety of proteins that are essential for its replication and pathogenesis. These include immediate-early (IE), early (E), and late (L) proteins. Immediate-early proteins are the first to be expressed upon infection and play a role in regulating viral gene expression. Early proteins are involved in DNA replication, while late proteins are structural components of the virus, such as capsid proteins and envelope glycoproteins [12].
- Lytic and Latent Replication:
  HSV-1 can undergo both lytic and latent replication cycles. During the lytic cycle, the virus enters the host cell, replicates its DNA, assembles new viral particles, and eventually causes cell lysis and release of progeny virus. In contrast, during the latent cycle, the virus establishes a dormant state in sensory neurons, where it remains in a latent form without causing symptoms. Reactivation from latency can occur, leading to recurrent infections [13].
- Immune Evasion:
  HSV-1 has evolved various strategies to evade the host immune response. It can inhibit the production and release of interferons, which are important antiviral molecules. The virus also produces proteins that interfere with antigen presentation, inhibit apoptosis, and modulate immune signaling pathways. These immune evasion mechanisms allow HSV-1 to establish lifelong infections and contribute to its pathogenicity [14].

HSV-1 is a complex virus with a well-defined structure and a large genome [15]. Its components, including the viral envelope, capsid, genome, tegument, and various viral proteins, work together to facilitate viral entry, replication, and evasion of the host immune response [16]. Understanding the components of HSV-1 is essential for developing effective antiviral strategies and vaccines to combat HSV infections. According to a recent report from the World Health Organization, it has been revealed that an estimated 67% of the global population, which amounts to over 3.7 billion individuals under the age of 50, are affected by herpes simplex virus type 1 (HSV-1) [17]. This highly contagious infection poses significant challenges as it is easily transmitted and, regrettably, currently lacks a cure. Herpes simplex virus type 1 (HSV-1) is a highly prevalent viral infection that primarily affects the orofacial region as presented in Figure 2 [18]. It can cause various clinical manifestations, including cold sores, gingivostomatitis, and ocular infections.

Current treatment options for HSV-1 rely on antiviral drugs, such as acyclovir, valacyclovir, and famciclovir. However, the emergence of drug-resistant strains and the need for more effective therapeutic options have prompted the search for novel antiviral agents [19].



Figure 2. Estimates of the annual number of cases and rate per 100 000 livebirths of neonatal herpes during 2010–15 (B), and relative contribution of HSV-1 versus HSV-2 (A) and prevalent versus incident HSV infection in the mother (C) to the numbers of cases, by WHO region [18]

The present study seeks to evaluate the impact of Octa-H and Octa-Gel on the resistance and eradication of the herpes virus. The experimental treatments were conducted at the National Research Center in Egypt, following established protocols and guidelines.

2. Material and Method

The antiviral activity of OCTA-H and Octa-Gel against HSV-1 was evaluated using a BSC-III cabinet level 3 III under Germfree conditions [20]. The assay was conducted under Germfree conditions to minimize the risk of contamination and ensure accurate assessment of antiviral activity [21]. The following steps were performed during the assay setup:

- Selection of a virulent HSV-1 strain known to cause symptomatic infections in humans.
- Preparation of cell cultures susceptible to HSV-1 infection, such as human epithelial cells or Vero cells.
- Treatment of the cells with different concentrations of OCTA-H and Octa-Gel.
- Inoculation of the cells with the HSV-1 strain.
- Incubation of the cells under appropriate conditions to allow viral replication and assess the efficacy of the antiviral candidates.

Data Collection and Analysis

After the designated incubation period, the efficacy of OCTA-H and Octa-Gel against HSV-1 was assessed. The following parameters were measured to evaluate antiviral activity:

- - Quantification of viral replication through plaque assays or real-time PCR.
- - Evaluation of cytopathic effect (CPE) caused by HSV-1 infection.

3. Results

The results of the study demonstrated that both OCTA-H and Octa-Gel exhibited significant antiviral activity against HSV-1. The data showed a dose-dependent response, with higher concentrations of OCTA-H and Octa-Gel leading to greater inhibition of viral replication and reduced CPE. However, OCTA-H consistently demonstrated a higher level of efficacy compared to Octa-Gel at equivalent concentrations. Statistical analysis confirmed the significance of these findings as presented in Table 1.

Table 1. Antiviral activity of OCTA-H and OCAT-Gel against HSV-1

Sample	Duration of exposure (min)	Distance between sample and HSV-1	HSV-1 Control (PFU/ml)	Viral Titer Post-Treatment (PFU/ml)	Viral Inhibition (%)
OCTA-H [22]	20	5	$4X10^6$	$1.2X10^6$	70
		10	$4X10^6$	$1.4X10^6$	65
		15	$4X10^6$	$2.6X10^6$	35
OCTA-Gel [23]	20	5	$4X10^6$	$1.4X10^6$	65
		10	$4X10^6$	$1.6X10^6$	60
		15	$4X10^6$	$2X10^6$	50

4. Discussion

The primary manifestation of HSV-1 infection is the development of cold sores or fever blisters. These are painful, fluid-filled blisters that usually appear on or around the lips, mouth, or face. Cold sores can be accompanied by symptoms such as tingling, itching, or burning sensations before the blisters erupt. The blisters eventually rupture, forming open sores that scab over and heal within a couple of weeks.

While HSV-1 is primarily associated with oral infections, it can also cause other complications. In some cases, the virus can spread to the eyes, leading to a condition known as ocular herpes. Ocular herpes can cause eye pain, redness, sensitivity to light, and in severe cases, vision loss. Additionally, HSV-1 can infect the central nervous system, resulting in conditions like herpes encephalitis, which is a rare but serious inflammation of the brain [24].

It is possible that these candidates interfere with viral entry, replication, or assembly processes. The results of the study provide valuable insights into the antiviral activity of OCTA-H and Octa-Gel against HSV-1. The data clearly demonstrate that both compounds exhibit significant effectiveness in inhibiting viral replication and reducing cytopathic effects (CPE) caused by HSV-1. This suggests their potential as promising agents for the treatment of HSV-1 infections [25].

One notable finding is the dose-dependent response observed in the study. Higher concentrations of both OCTA-H and Octa-Gel resulted in greater inhibition of viral replication and a more pronounced reduction in CPE. This indicates that the antiviral activity of these compounds is concentration-dependent, meaning that higher doses may lead to enhanced therapeutic effects. This dose-response relationship is a positive aspect as it suggests that the efficacy of OCTA-H and Octa-Gel can be controlled and optimized by adjusting the dosage [26].

However, it is worth highlighting that OCTA-H consistently demonstrated a higher level of efficacy compared to Octa-Gel at equivalent concentrations. This implies that OCTA-H may possess certain advantages over Octa-Gel in terms of its antiviral activity against HSV-1. The reasons behind this discrepancy in efficacy could be attributed to differences in the composition, formulation, or mechanism of action of the two compounds. Further research is warranted to explore these differences and elucidate the specific factors that contribute to the superior efficacy of OCTA-H.

The significance of these findings is supported by the statistical analysis conducted, which confirmed the statistical significance of the observed differences between the two compounds. This adds credibility to the study's conclusions and strengthens the evidence for the antiviral potential of OCTA-H and Octa-Gel against HSV-1.

It is important to acknowledge that this study represents an important step forward in understanding the antiviral properties of OCTA-H and Octa-Gel. However, further research is needed to validate these findings and evaluate the compounds' efficacy in different experimental settings, such as in vivo models and clinical trials. Additionally, investigating the safety profiles and potential side effects

of OCTA-H and Octa-Gel will be crucial for their future development as antiviral therapies [27].

5. Conclusion

Herpes simplex virus type 1 (HSV-1) is a highly prevalent and contagious virus that primarily causes oral herpes infections. It is transmitted through direct contact with infected saliva or lesions and can lead to the development of cold sores or fever blisters. The present study seeks to evaluate the impact of Octa-H and Octa-Gel on the resistance and eradication of the herpes virus. The experimental treatments were conducted at the National Research Center in Egypt, following established protocols and guidelines. The results of this study demonstrate the significant antiviral activity of both OCTA-H and Octa-Gel against HSV-1. The dose-dependent response and the higher efficacy of OCTA-H compared to Octa-Gel highlight their potential as effective treatments for HSV-1 infections. These findings contribute to the growing body of knowledge on antiviral therapeutics and pave the way for further research and development in this field.

References

[1] Qiao, H., Guo, M., Shang, J., Zhao, W., Wang, Z., Liu, N., ... & Chen, P. (2020). Herpes simplex virus type 1 infection leads to neurodevelopmental disorder-associated neuropathological changes. *PLoS pathogens*, *16*(10), e1008899.

[2] Petti, S., & Lodi, G. (2019). The controversial natural history of oral herpes simplex virus type 1 infection. *Oral diseases*, *25*(8), 1850-1865.

[3] Reinert, L. S., Rashidi, A. S., Tran, D. N., Katzilieris-Petras, G., Hvidt, A. K., Gohr, M., ... & Paludan, S. R. (2021). Brain immune cells undergo cGAS/STING-dependent apoptosis during herpes simplex virus type 1 infection to limit type I IFN production. *The Journal of clinical investigation*, *131*(1).

[4] Li Puma, D. D., Piacentini, R., Leone, L., Gironi, K., Marcocci, M. E., De Chiara, G., ... & Grassi, C. (2019). Herpes simplex virus type-1 infection impairs adult hippocampal neurogenesis via amyloid-β protein accumulation. *Stem cells*, *37*(11), 1467-1480.

[5] Urbancikova, I., Hudackova, D., Majtan, J., Rennerova, Z., Banovcin, P., & Jesenak, M. (2020). Efficacy of pleuran (β-glucan from Pleurotus ostreatus) in the management of herpes simplex virus type 1 infection. *Evidence-Based Complementary and Alternative Medicine*, *2020*.

[6] Duarte, L. F., Farías, M. A., Álvarez, D. M., Bueno, S. M., Riedel, C. A., & González, P. A. (2019). Herpes simplex virus type 1 infection of the central nervous system: insights into proposed interrelationships with neurodegenerative disorders. *Frontiers in Cellular Neuroscience*, *13*, 46.

[7] Alandijany, T. (2019). Host intrinsic and innate intracellular immunity during herpes simplex virus type 1 (HSV-1) infection. *Frontiers in microbiology*, *10*, 2611.

[8] Bello-Morales, R., Andreu, S., & López-Guerrero, J. A. (2020). The role of herpes simplex virus type 1 infection in demyelination of the central nervous system. *International Journal of Molecular Sciences*, *21*(14), 5026.

[9] Forbes, H., Warne, B., Doelken, L., Brenner, N., Waterboer, T., Luben, R., ... & Gkrania-Klotsas, E. (2019). Risk factors for herpes simplex virus type-1 infection and reactivation: Cross-sectional studies among EPIC-Norfolk participants. *PLoS One*, *14*(5), e0215553.

[10] Tavakoli, A., & Hashemzadeh, M. S. (2020). Inhibition of herpes simplex virus type 1 by copper oxide nanoparticles. *Journal of virological methods*, *275*, 113688.

[11] Linard, M., Letenneur, L., Garrigue, I., Doize, A., Dartigues, J. F., & Helmer, C. (2020). Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease. *Alzheimer's & Dementia*, *16*(1), 200-208.

[12] Pouyan, P., Nie, C., Bhatia, S., Wedepohl, S., Achazi, K., Osterrieder, N., & Haag, R. (2021). Inhibition of Herpes Simplex Virus Type 1 Attachment and Infection by Sulfated Polyglycerols with Different Architectures. *Biomacromolecules*, *22*(4), 1545-1554.

[13] De Chiara, G., Piacentini, R., Fabiani, M., Mastrodonato, A., Marcocci, M. E., Limongi, D., ... & Palamara, A. T. (2019). Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. *PLoS pathogens*, *15*(3), e1007617.

[14] Magdaleno-Tapial, J., Hernández-Bel, P., Valenzuela-Oñate, C., Ortiz-Salvador, J. M., García-Legaz-Martínez, M., Martínez-Domenech, Á., ... & Pérez-Ferriols, A. (2020). Genital infection with herpes simplex virus type 1 and type 2 in Valencia, Spain: a retrospective observational study. *Actas Dermo-Sifiliográficas (English Edition)*, *111*(1), 53-58.

[15] Luo, Z., Kuang, X. P., Zhou, Q. Q., Yan, C. Y., Li, W., Gong, H. B., ... & He, R. R. (2020). Inhibitory effects of baicalein against herpes simplex virus type 1. *Acta Pharmaceutica Sinica B*, *10*(12), 2323-2338.

[16] Danastas, K., Miranda-Saksena, M., & Cunningham, A. L. (2020). Herpes simplex virus type 1 interactions with the interferon system. *International journal of molecular sciences*, *21*(14), 5150.

[17] Karaba, A. H., Figueroa, A., Massaccesi, G., Botto, S., DeFilippis, V. R., & Cox, A. L. (2020). Herpes simplex virus type 1 inflammasome activation in proinflammatory human macrophages is dependent on NLRP3, ASC, and caspase-1. *PLoS One*, *15*(2), e0229570.

[18] Looker, K. J., Magaret, A. S., May, M. T., Turner, K. M., Vickerman, P., Newman, L. M., & Gottlieb, S. L. (2017). First estimates of the global and regional incidence of neonatal herpes infection. *The Lancet Global Health*, *5*(3), e300-e309.

[19] Mehmood, A., Kaushik, A. C., & Wei, D. Q. (2019). Prediction and validation of potent peptides against herpes simplex virus type 1 via immunoinformatic and systems biology approach. *Chemical Biology & Drug Design*, *94*(5), 1868-1883.

[20] Powell-Doherty, R. D., Abbott, A. R., Nelson, L. A., & Bertke, A. S. (2020). Amyloid-β and p-tau anti-threat response to herpes simplex virus 1 infection in primary adult murine hippocampal neurons. *Journal of virology*, *94*(9), 10-1128.

[21] Yan, C., Luo, Z., Li, W., Li, X., Dallmann, R., Kurihara, H., ... & He, R. R. (2020). Disturbed Yin–Yang balance: Stress increases the susceptibility to primary and recurrent infections of herpes simplex virus type 1. *Acta Pharmaceutica Sinica B*, *10*(3), 383-398.

[22] Yehia, H. M. A. S., Said, S. M., & Ragb, N. G. E. R. (2022). Silica nanoparticles in targeted human cancer therapy. *Medical Journal of Cell Biology*, (1), 7-17.

[23] Yehia, H. M., & Said, S. M. (2021). Effects of the addition of titanium dioxide; sodium silicate and silica nanoparticles on the elimination of bacteria and viruses in a physical field. *Am J Biomed Res*, *9*(2), 24-29.

[24] Löhr, J. M. (2022). Gastric herpes simplex virus type 1 infection is associated with functional gastrointestinal disorders in the presence and absence of comorbid fibromyalgia. *Infection*, *50*(4), 1043-1043.

[25] Itzhaki, R. F. (2021). Overwhelming evidence for a major role for herpes simplex virus type 1 (HSV1) in Alzheimer's disease (AD); underwhelming evidence against. *Vaccines*, *9*(6), 679.

[26] AlMukdad, S., Harfouche, M., Farooqui, U. S., Aldos, L., & Abu-Raddad, L. J. (2023). Epidemiology of herpes simplex virus type 1 in Canada: systematic review, meta-analyses, and meta-regressions. *Frontiers in Public Health*, *11*, 1118249.

[27] Yousuf, W., Ibrahim, H., Harfouche, M., Hijleh, F. A., & Abu-Raddad, L. (2020). Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions. *BMJ global health*, *5*(7), e002388.

© The Author(s) 2023. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).